42.70
price down icon1.51%   -0.946
 
loading
Precedente Chiudi:
$43.65
Aprire:
$43.86
Volume 24 ore:
63,266
Relative Volume:
0.05
Capitalizzazione di mercato:
$5.20B
Reddito:
$10.60M
Utile/perdita netta:
$-252.45M
Rapporto P/E:
-13.78
EPS:
-3.1
Flusso di cassa netto:
$-158.91M
1 W Prestazione:
-13.97%
1M Prestazione:
-7.96%
6M Prestazione:
+45.68%
1 anno Prestazione:
+633.62%
Intervallo 1D:
Value
$42.59
$44.68
Intervallo di 1 settimana:
Value
$39.50
$50.32
Portata 52W:
Value
$5.93
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Nome
Avidity Biosciences Inc
Name
Telefono
858-401-7900
Name
Indirizzo
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Dipendente
253
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-07
Name
Ultimi documenti SEC
Name
RNA's Discussions on Twitter

Confronta RNA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
RNA 42.63 5.20B 10.60M -252.45M -158.91M -3.10
VRTX 445.50 115.74B 10.63B -479.80M -1.35B 13.33
REGN 737.53 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 585.04 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 247.28 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.21 24.49B 3.30B -501.07M 1.03B 11.54

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-24 Iniziato Goldman Buy
2024-08-28 Iniziato Barclays Overweight
2024-05-03 Iniziato BofA Securities Buy
2024-03-14 Iniziato Cantor Fitzgerald Overweight
2023-05-22 Aggiornamento Evercore ISI In-line → Outperform
2023-03-31 Downgrade Evercore ISI Outperform → In-line
2022-07-20 Iniziato Chardan Capital Markets Buy
2022-07-12 Iniziato Raymond James Strong Buy
2021-09-07 Iniziato Evercore ISI Outperform
2021-06-17 Iniziato Needham Buy
2021-04-26 Ripresa Credit Suisse Outperform
2020-07-07 Iniziato Cowen Outperform
2020-07-07 Iniziato Credit Suisse Outperform
2020-07-07 Iniziato SVB Leerink Outperform
2020-07-07 Iniziato Wells Fargo Overweight
Mostra tutto

Avidity Biosciences Inc Borsa (RNA) Ultime notizie

pulisher
Nov 20, 2024

Avidity Biosciences director Arthur Levin sells $139,972 in stock By Investing.com - Investing.com South Africa

Nov 20, 2024
pulisher
Nov 20, 2024

Avidity Biosciences' chief HR officer Teresa McCarthy sells $1.03m in stock - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Mutual of America Capital Management LLC Cuts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Research Analysts Set Expectations for RNA FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

Los Angeles Capital Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

State of New Jersey Common Pension Fund D Buys Shares of 44,898 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

12,319 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by Assetmark Inc. - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Avidity Biosciences (NASDAQ:RNA) Shares Down 7.8%Time to Sell? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

RA Capital Management's Strategic Acquisition in Avidity Bioscie - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Avidity Biosciences unveils new cardiology development candidates - BioWorld Online

Nov 14, 2024
pulisher
Nov 14, 2024

RNA Stock Hits Record High on Entering the Cardiac Disease Space - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

US Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News - Yahoo! Voices

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences stock soars to all-time high of $50.86 By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 - Quantisnow

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences stock soars to all-time high of $50.86 - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences jumps 16%; reaches all-time high (RNA:NASDAQ) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year HighShould You Buy? - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Assessing Avidity Biosciences: Insights From 10 Financial Analysts - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire

Nov 13, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences (RNA) Stock Surges On Positive AOC 1020 Trial Results - Barchart

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Unveils Advances in Cardiology Research - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences, Inc. Announces AOC 1072 and AOC 1086 as Initial Precision Cardiology Development Candidates and Shared First Look At Its Next-Generation Technology Innovations - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - PR Newswire

Nov 12, 2024
pulisher
Nov 09, 2024

Selling US$1.0m Of Avidity Biosciences Stock Rewarded Insiders - Simply Wall St

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance

Nov 09, 2024
pulisher
Nov 09, 2024

431,210 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Fiera Capital Corp - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences CFO sells $4.8 million in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences CFO sells $4.8 million in stock By Investing.com - Investing.com Canada

Nov 09, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition in Avidi - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - BioSpace

Nov 08, 2024
pulisher
Nov 08, 2024

Avidity Biosciences Reports Strong Q3 Progress and Outlook - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Avidity Bio's DMD Drug Shows 25% Dystrophin Boost; Reports $1.6B Cash Position | RNA Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 04, 2024

Avidity Biosciences (NASDAQ:RNA) Trading Up 6.5%What's Next? - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Vanguard Group Inc's Strategic Acquisition in Avidity Biosciences Inc - GuruFocus.com

Nov 04, 2024
pulisher
Nov 02, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused o - GuruFocus.com

Nov 02, 2024
pulisher
Oct 31, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 – Company AnnouncementFT.com - Financial Times

Oct 31, 2024
pulisher
Oct 31, 2024

Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Avidity Biosciences advances FSHD therapy trial By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Avidity Biosciences target held at $59 by Goldman Sachs - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Chardan Capital Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00 - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Faciosca - StreetInsider.com

Oct 30, 2024

Avidity Biosciences Inc Azioni (RNA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Avidity Biosciences Inc Azioni (RNA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
McCarthy Teresa
Chief Human Resources Officer
Nov 18 '24
Sale
41.14
25,000
1,028,520
94,018
LEVIN ARTHUR A
Director
Nov 19 '24
Option Exercise
1.24
3,323
4,121
18,153
LEVIN ARTHUR A
Director
Nov 19 '24
Sale
42.12
3,323
139,973
14,830
MacLean Michael F
Chief Financial Officer
Nov 06 '24
Option Exercise
8.43
79,057
666,064
159,275
MacLean Michael F
Chief Financial Officer
Nov 06 '24
Sale
45.56
106,319
4,843,979
94,093
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):